secwatch.observer — SEC 8-K summary
======================================

Issuer:     PAVmed Inc. (PAVM)
CIK:        0001624326
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001641172-25-023729
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PAVmed Q2 net loss $13.3M ($0.74/share); Lucid EsoGuard rev $1.2M on 2,756 tests
--------------------------------------------------------------------------------

- GAAP net loss $13.3M ($0.74 diluted EPS); non-GAAP adjusted loss $1.8M ($0.11/share).
- Lucid processed 2,756 EsoGuard tests and recognized $1.2M revenue; CAC meeting on Medicare LCD set Sept 4.
- Lucid raised $16.1M in public offering; Veris completed $2.5M direct equity financing at $35M pre-money valuation.
- Veris advancing implantable monitor through FDA clearance; partnered with OSU-The James for Cancer Care Platform.
- Cash $4.0M at June 30 vs $1.2M at Dec 31, 2024; operating expenses $4.7M including $0.2M stock comp.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1624326/000164117225023729/0001641172-25-023729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1624326/000164117225023729/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer